Showing 6451-6460 of 7364 results for "".
- DBV Technologies Presents Breakthrough Data at EAACI-WAO Congresshttps://practicaldermatology.com/news/20130702-dbv_technologies_presents_breakthrough_data_at_eaaci-wao_congress/2459506/DBV Technologies presented six clinical and preclinical presentations on Epicutaneaous Immunotherapy (EPIT) at the European Academy of Allergy & Clinical Immunology & World Allergy Organization & World Allergy & Asthma Congress (EAACI-WAO) in Milan, Italy. DBV's Viaskin technology was highlighted in
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with
- ASDS Launches Cosmetic Dermatology Fellowship Programhttps://practicaldermatology.com/news/20130627-asds_launches_cosmetic_dermatology_fellowship_program/2459508/The American Society for Dermatologic Surgery (ASDS) launched a fellowship accreditation program designed to promote post-residency training in cosmetic dermatologic surgery procedures. According to ASDS President Timothy C. Flynn, MD, fellowship training will give young dermatologists a solid educa
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials
- Artefill Shows Efficacy for Atrophic Acne Scars: Datahttps://practicaldermatology.com/news/20130624-artefill_shows_efficacy_for_atrophic_acne_scars_data/2459513/Recently reported data suggest that ArteFill dermal filler is an effective option to treat atrophic acne scars. Suneva Medical shared promising six-month results from its randomized, double-blinded, multi-center, controlled study that evaluated the
- Geneticists Research Cleft Palate and Skin Deformitieshttps://practicaldermatology.com/news/20130614-geneticists_research_cleft_palate_and_skin_deformities/2459514/Scientists at Cold Spring Harbor Laboratory (CSHL) solved the mystery of why some infants are born with cleft palate and major deformities of the skin and limbs, while other infants with the same genetic mutation bear little or no sign of the illness, called Ectodactyly, Ectodermal dysplasia, Clefti
- Steve Perry Undergoes Cancer Surgeryhttps://practicaldermatology.com/news/20130611-steve_perry_undergoes_cancer_surgery/2459515/Former Journey singer Steve Perry had a cancerous mole on his right cheek removed recently. Test results found it positive for melanoma. Perry had to undergo two procedures to rid his skin of all of the cancer cells, according to his physicians, and no further treatment will be necessary.
- Stelara Approved for Self-Administrationhttps://practicaldermatology.com/news/20130611-stelara_approved_for_self-administration/2459518/The FDA has approved Stelara (ustekinumab) for self-administration. Previously intended for subcutaneous administration under the supervision of a physician, Stelara can now be administered by patients at home. The drug is approved for the treatment of adult patients with moderate to severe plaque p
- National Psoriasis Foundation Awards Research Grantshttps://practicaldermatology.com/news/20130610-national_psoriasis_foundation_awards_research_grants/2459519/Six scientists received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for psoriasis and psoriatic arthritis. Theoharis Theoharides, MD, PhD received a
- Suneva Selects Quinnova to Co-promote ReFissahttps://practicaldermatology.com/news/20130610-suneva_selects_quinnova_to_co-promote_refissa/2459520/Suneva Medical, Inc. selected Quinnova Pharmaceuticals, LLC to co-promote ReFissa. ReFissa is the only FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.